Feature | September 06, 2013

Researchers Aim to Use Light — Not Electric Jolts — to Restore Healthy Heartbeats

Johns Hopkins-led research team explores the field of optogenetics

September 6, 2013 — When a beating heart slips into an irregular, life-threatening rhythm, the treatment is well known: deliver a burst of electric current from a pacemaker or defibrillator. But because the electricity itself can cause pain, tissue damage and other serious side-effects, a Johns Hopkins-led research team wants to replace these jolts with a kinder, gentler remedy: light.

In a paper published Aug. 28, 2013, in the online journal Nature Communications, five biomedical engineers from Johns Hopkins and Stony Brook universities described their plan to use biological lab data and an intricate computer model to devise a better way to heal ailing hearts. Other scientists are already using light-sensitive cells to control certain activities in the brain. The Johns Hopkins-Stony Brook researchers say they plan to give this technique a cardiac twist so that doctors in the near future will be able to use low-energy light to solve serious heart problems such as arrhythmia.

“Applying electricity to the heart has its drawbacks,” said the project’s supervisor, Natalia Trayanova, the Murray B. Sachs professor of biomedical engineering at Johns Hopkins. “When we use a defibrillator, it’s like blasting open a door because we don’t have the key. It applies too much force and too little finesse. We want to control this treatment in a more intelligent way. We think it’s possible to use light to reshape the behavior of the heart without blasting it.”

To achieve this, Trayanova’s team is diving into the field of optogenetics, which is only about a decade old. Pioneered by scientists at Stanford, optogenetics refers to the insertion of light-responsive proteins called opsins into cells. When exposed to light, these proteins become tiny portals within the target cells, allowing a stream of ions — an electric charge — to pass through. Early researchers have begun using this tactic to control the bioelectric behavior of certain brain cells, forming a first step toward treating psychiatric disorders with light.

In the Nature Communications paper, the researchers reported that they had successfully tested this same technique on a heart -- one that “beats” inside a computer. Trayanova has spent many years developing highly detailed computer models of the heart that can simulate cardiac behavior from the molecular and cellular levels all the way up to that of the heart as a whole.

As detailed in the journal article, the Johns Hopkins computer model for treating the heart with light incorporates biological data from the Stony Brook lab of Emilia Entcheva, an associate professor of biomedical engineering. The Stony Brook collaborators are working on techniques to make heart tissue light-sensitive by inserting opsins into some cells. They also will test how these cells respond when illuminated.

In Trayanova’s own lab, her team members will use this model to conduct virtual experiments. They will try to determine how to position and control the light-sensitive cells to help the heart maintain a healthy rhythm and pumping activity. They will also try to gauge how much light is needed to activate the healing process. The overall goal is to use the computer model to push the research closer to the day when doctors can begin treating their heart patients with gentle light beams. The researchers say it could happen within a decade.

After the technology is honed through the computer modeling tests, it could be incorporated into light-based pacemakers and defibrillators.

For more information: www.nature.com/ncomms

Related Content

EpiAccess System, EpiEP, Mount Sinai New York, epicardial access
News | Ablation Systems| August 22, 2016
August 22, 2016 — The Mount Sinai Hospital is the first site in the New York metropolitan area to pioneer a new appro
warfarin, long-term stability, atrial fibrillation, DCRI study, Sean Pokorney
News | Antiplatelet and Anticoagulation Therapies| August 16, 2016
August 16, 2016 — Warfarin prescribed to prevent strokes in...
Sponsored Content | Videos | Inventory Management| August 15, 2016
Pacemakers, stents and bandages — keeping tracking of what is on hand and accurately capturing charges can be a chall
News | EP Lab| August 12, 2016
August 12, 2016 — Electrophysiology ablation navigation system company Stereotaxis Inc.
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
 
Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Feature | Left Atrial Appendage (LAA) Occluders| August 01, 2016 | Dave Fornell
Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in th
pros and cons of new anticoagulation therapies, anticoagulants, dabigatran, Pradaxa, novel oral anticoagulants, NOACs, rivaroxaban, Xarelto, apixaban, Eliquis
Feature | Antiplatelet and Anticoagulation Therapies| July 26, 2016 | Heidi Olson, Pharm.D
With the recent introduction of several novel oral...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing| July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
Overlay Init